Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

Blood

Volumn 113, Issue 16, 2009, Pages 3781-3791

  Ocio, Enrique M ^a,b   Maiso, Patricia ^a   Xi, Chen ^a   Garayoa, Mercedes ^a   Álvarez Fernández, Stela ^a   San Segundo, Laura ^a   Vilanova, David ^a   López Corral, Lucía ^a   Montero, Juan C ^a   Hernández Iglesias, Teresa ^a   De Álava, Enrique ^a   Galmarini, Carlos ^c   Avilés, Pablo ^c   Cuevas, Carmen ^c   San Miguel, Jesús F ^a,b   Pandiella, Atanasio ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CHECKPOINT KINASE 2; DEXAMETHASONE; DOUBLE STRANDED DNA; DOXORUBICIN; HISTONE H2AX; LENALIDOMIDE; MELPHALAN; N [[ 5 (ACETYLOXY) 6,6A,7,13,14,16 HEXAHYDRO 8,14 DIHYDROXY 9 METHOXY 4,10,17 TRIMETHYL 7,13 IMINO 12H 1,3 DIOXOLO[7,8]ISOQUINO[3,2 B][3]BENZAZOCIN 16 YL]METHYL] 3 [3 (TRIFLUOROMETHYL)PHENYL] 2E PROPENAMIDE; PROTEIN P53; UNCLASSIFIED DRUG; ZALYPSIS; H2AFX PROTEIN, HUMAN; HISTONE; PM00104; PROTEIN SERINE THREONINE KINASE; TETRAHYDROISOQUINOLINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL CYCLE ARREST; CELL DEATH; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MARINE ENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR; WILD TYPE; XENOGRAFT; ANIMAL; BIOSYNTHESIS; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MOUSE MUTANT; MUTATION; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DNA BREAKS, DOUBLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONES; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; MUTATION; PHOSPHORYLATION; PLASMA CELLS; PROTEIN-SERINE-THREONINE KINASES; TETRAHYDROISOQUINOLINES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65549099309     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-177774     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol. 2008;26:313-325.
3. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030. (Pubitemid 43357806)
4. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498. (Pubitemid 41007864)
6. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
7. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132. (Pubitemid 350146107)
8. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142. (Pubitemid 350146108)
9. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
10. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484-5492.
11. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576-584. (Pubitemid 46224235)
12. Fontana A, Cavaliere P, Wahidulla S, Naik CG, Cimino GA. Alkaloid from the Marine Nudibrach Jorunna funebris. Tetrahedrom. 2000;56:7305-7308.
13. James MF, Faulkner DJ. Antimicrobial metabolites of the sponge Reniera sp. J Am Chem Soc. 1982;104:265-269.
14. Oku N, Matsunaga S, van Soest RW, Fusetani N. Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp. J Nat Prod. 2003;66:1136-1139. (Pubitemid 37034057)
15. LePage D, Sasak H, Guillen MJ, et al. Antitumor activity of Zalypsis® (PM00104) in experimental models of bladder, gastric and liver cancer. AACR Meeting Abstracts. 2007;C62.
16. LePage D, Sasak H, Cheney L, et al. Antitumor activity of Zalypsis® in human pancreas tumors. AACR Meeting Abstracts. 2007;1519.
17. Greiner T, Maier A, Bausch N, et al. Preclinical evaluation of PM00104 to support the selection of tumor indications for clinical development. AACR Meeting Abstracts. 2007;C60.
18. Elices M, Grant W, Harper C, et al. The novel compound PM00104 exhibits significant in vivo activity against breast tumors. AACR Meeting Abstracts. 2005;147a.
19. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66:5781-5789. (Pubitemid 43927132)
20. Maiso P, Ocio EM, Garayoa M, et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol. 2008;141:470-482. (Pubitemid 351550551)
21. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002;29:17-20.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
23. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
24. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205-219. (Pubitemid 38167313)
25. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med. 2005;11:725-730.
26. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739-745. (Pubitemid 350217064)
27. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol. 2008;615:201-221.
28. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609-3617. (Pubitemid 41609200)